MA32364B1 - Procedes de suivi de la modulation de l'activite kinase du recepteur du facteur de croissance des fibroblastes et leurs utilisations - Google Patents

Procedes de suivi de la modulation de l'activite kinase du recepteur du facteur de croissance des fibroblastes et leurs utilisations

Info

Publication number
MA32364B1
MA32364B1 MA33374A MA33374A MA32364B1 MA 32364 B1 MA32364 B1 MA 32364B1 MA 33374 A MA33374 A MA 33374A MA 33374 A MA33374 A MA 33374A MA 32364 B1 MA32364 B1 MA 32364B1
Authority
MA
Morocco
Prior art keywords
methods
kinase activity
modulation
monitoring
growth factor
Prior art date
Application number
MA33374A
Other languages
Arabic (ar)
English (en)
Inventor
Porta Diana Graus
Vito Guagnano
Estelle Marrer
Pablo Verdes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32364B1 publication Critical patent/MA32364B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne, de façon générale, des procédés de diagnostic in vitro et, en particulier, l'utilisation, en tant que biomarqueur, d'un composé choisi dans le groupe constitué du facteur de croissance des fibroblastes 23 (fgf23), du phosphore inorganique (p), du produit du phosphore inorganique et du calcium total (p x cat), de l'ostéopontine (opn) et de l'hormone parathyroïdienne (hpt). Lesdits biomarqueurs peuvent être utilisés pour le suivi de la modulation de l'activité kinase du récepteur du facteur de croissance des fibroblastes (fgfr), en particulier de son inhibition, et/ou de la survenue d'effets secondaires associés à l'inhibition du fgfr. L'invention concerne encore des procédés et nécessaires associés à ces utilisations.
MA33374A 2008-04-29 2010-11-25 Procedes de suivi de la modulation de l'activite kinase du recepteur du facteur de croissance des fibroblastes et leurs utilisations MA32364B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08155401 2008-04-29
EP08156856 2008-05-23
PCT/EP2009/055127 WO2009133101A1 (fr) 2008-04-29 2009-04-28 Procédés de suivi de la modulation de l'activité kinase du récepteur du facteur de croissance des fibroblastes et leurs utilisations

Publications (1)

Publication Number Publication Date
MA32364B1 true MA32364B1 (fr) 2011-06-01

Family

ID=40792814

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33374A MA32364B1 (fr) 2008-04-29 2010-11-25 Procedes de suivi de la modulation de l'activite kinase du recepteur du facteur de croissance des fibroblastes et leurs utilisations

Country Status (16)

Country Link
US (2) US20110045511A1 (fr)
EP (1) EP2271943A1 (fr)
JP (3) JP5539963B2 (fr)
KR (1) KR101660544B1 (fr)
CN (2) CN102016592A (fr)
BR (1) BRPI0911491A2 (fr)
CA (1) CA2720888A1 (fr)
IL (2) IL208725A (fr)
MA (1) MA32364B1 (fr)
MX (2) MX342553B (fr)
NZ (1) NZ609066A (fr)
RU (2) RU2010148531A (fr)
SG (1) SG190592A1 (fr)
TW (1) TWI526687B (fr)
WO (1) WO2009133101A1 (fr)
ZA (1) ZA201007119B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US20120258940A1 (en) * 2009-12-18 2012-10-11 Giordano Caponigro Method for treating haematological cancers
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
US20130345234A1 (en) * 2011-03-17 2013-12-26 Humphrey Athelstan Roy Gardner Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
WO2013074492A1 (fr) * 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Procédés de traitement du cancer
EP2830626B1 (fr) * 2012-03-30 2019-01-02 Novartis AG Inhibiteur de fgfr destiné au traitement de troubles hypophosphatémiques
CA2866321A1 (fr) * 2012-04-03 2013-10-10 Novartis Ag Combinaisons d'inhibiteurs de tyrosine kinase et leur utilisation
CA2876689C (fr) 2012-06-13 2022-04-26 Incyte Corporation Composes tricycliques substitues utilises comme inhibiteurs de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (fr) 2015-02-20 2024-02-27 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
RU2634573C1 (ru) * 2016-07-05 2017-10-31 государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ стратификации риска поражения сердечно-сосудистой системы у пациентов с хронической болезнью почек
JOP20190080A1 (ar) * 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7416856B2 (en) * 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
CA2398603A1 (fr) * 2000-02-15 2001-08-23 Amgen, Inc. Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
JP2002014095A (ja) * 2000-06-30 2002-01-18 Srl Inc 血液検査データ解析及び表示システム並びに方法
JP2004504063A (ja) * 2000-07-19 2004-02-12 アドバンスド　リサーチ　＆　テクノロジー　インスティテュート 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
GB0023080D0 (en) * 2000-09-20 2000-11-01 Univ Liverpool Prognostic indicator
US20050004348A1 (en) * 2002-12-23 2005-01-06 Miyamoto Ken-Ichi Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
US7259144B2 (en) * 2003-02-21 2007-08-21 Curagen Corporation Methods for diagnosing and treatment of hyperphosphatemic conditions using FGF20 polypeptides
WO2004083381A2 (fr) * 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Polynucleotides, polypeptides et mutants des recepteurs 1 du facteur de croissance des fibroblastes
US7078528B2 (en) * 2003-07-02 2006-07-18 East Carolina University Biimidazole diamide anion binding agents
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2007067968A2 (fr) * 2005-12-08 2007-06-14 Novartis Ag Effets d'inhibiteurs de fgfr3 sur la transcription genetique
JP2007178356A (ja) * 2005-12-28 2007-07-12 Japan Health Science Foundation 骨質を評価する方法，骨質の評価キット，骨質劣化予防又は改善剤のスクリーニング方法，及び骨質劣化予防又は改善剤のスクリーニング用キット
JP2008017790A (ja) * 2006-07-14 2008-01-31 Hiroshima Univ 石灰化調節剤及びそのスクリーニング法
DE102007026877A1 (de) * 2007-06-08 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
US20110183434A1 (en) * 2008-01-17 2011-07-28 Myles Wolf Diagnostic methods and kits using fibroblast growth factor-23

Also Published As

Publication number Publication date
JP2011519043A (ja) 2011-06-30
IL229822A0 (en) 2014-01-30
EP2271943A1 (fr) 2011-01-12
US20150323548A1 (en) 2015-11-12
US20110045511A1 (en) 2011-02-24
JP2014142349A (ja) 2014-08-07
RU2010148531A (ru) 2012-06-10
RU2013131640A (ru) 2015-01-20
CA2720888A1 (fr) 2009-11-05
CN102016592A (zh) 2011-04-13
TW200949247A (en) 2009-12-01
NZ609066A (en) 2014-07-25
JP2015172584A (ja) 2015-10-01
CN103353532A (zh) 2013-10-16
SG190592A1 (en) 2013-06-28
KR101660544B1 (ko) 2016-09-27
IL208725A (en) 2014-06-30
KR20100135956A (ko) 2010-12-27
ZA201007119B (en) 2016-02-24
MX342553B (es) 2016-10-04
JP5539963B2 (ja) 2014-07-02
IL208725A0 (en) 2010-12-30
TWI526687B (zh) 2016-03-21
CN103353532B (zh) 2016-05-11
IL229822A (en) 2016-02-29
BRPI0911491A2 (pt) 2016-01-05
WO2009133101A1 (fr) 2009-11-05
AU2009242176A1 (en) 2009-11-05
MX2010011959A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
MX342553B (es) Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.
WO2010031056A3 (fr) Procédés et compositions pour moduler l'activité ire1, src, et abl
EP1931637A4 (fr) Methodes permettant de moduler l'activite induite par la neurotrophine
WO2011002850A8 (fr) Procédés pour déterminer la présence et/ou la concentration d'un analyte dans un échantillon
NZ597273A (en) Trimethylamine-containing compounds for diagnosis and prediction of disease
WO2008048230A3 (fr) Procédés d'identification de cibles biologiques et instrumentation d'identification de cibles biologiques
EP2480210A4 (fr) Particules de phosphate de calcium uniformes, rigides, sphériques, nanoporeuses chargées de principe actif et leurs méthodes de fabrication et d'utilisation
EP1804660A4 (fr) Systeme et procedes permettant d'evaluer la voie neuromusculaire avant un test des nerfs
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
EP2546649A3 (fr) Biomarqueurs de la stéatose hépatique et procédés les utilisant
WO2008115518A3 (fr) Biomarqueurs de l'activité sirtuine et procédés d'utilisation de ceux-ci
ATE486285T1 (de) Verfahren zur früherkennung von krebs
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
PL2341344T3 (pl) Sposób diagnozowania wielotorbielowatości nerek
WO2007134028A3 (fr) Biomarqueurs pour la dépression et méthodes d'utilisation de ceux-ci
SG10201407036YA (en) Markers of Endothelial Progenitor Cells and Uses Thereof
DK2005162T3 (da) Screeningsmetode
WO2009055823A3 (fr) Procédé permettant de prédire la réactivité du cancer de la poitrine à une chimiothérapie de type polyamine
EP2296693A4 (fr) Compositions destinées à amplifier l' activité antibactérienne de la myéloperoxydase et leurs procédés d' utilisation
ATE552378T1 (de) Verfahren zu bekämpfung von lipophilen extraktivstoffen in akazienholzstoff und faser
UA95469C2 (ru) Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применения в терапии
WO2012178188A3 (fr) Panel diagnostique moléculaire de troubles gastro-intestinaux éosinophiles
NZ593221A (en) Detecting and monitoring left ventricular hypertrophy and congestive heart failure by profiling biomarkers
WO2009007649A3 (fr) Dispositif et procede d'identification et de determination de groupes sanguins
WO2010080640A3 (fr) Procédé de détection d'une liaison ligand-récepteur grâce à la modulation du ph